NICE give final guidance approving Pfizer’s lung cancer treatment
NICE has published guidance recommending the use of Pfizer’s Lorviqua for a certain form of lung cancer on the NHS. The drug has been recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after: alectinib or ceritinib as the